



Presbyterian Health Plan, Inc.
 Presbyterian Insurance Company, Inc.

Pharmacy and Therapeutics Update

Formulary and pharmacy benefit updates for Presbyterian Healthcare Services professionals, providers and staff

FIRST QUARTER 2022

Pharmacy and Therapeutics (P&T) Committee Decisions Effective March 1, 2022

The Presbyterian Health Plan, Inc., and Presbyterian Insurance Company, Inc., (Presbyterian) Pharmacy and Therapeutics (P&T) Committee meets quarterly to promote the appropriate use of drugs to maintain the Presbyterian formularies and support our network of practitioners. The P&T Committee met on **Jan. 19, 2022**, and we would like to share the decisions made at the meeting that affect our formularies and pharmacy benefits.

Centennial, Commercial and Metal Formulary Updates

Drug Name	Therapeutic Class	Centennial Care*	Commercial*	Metal Level Plans*
Formulary Additions				
Dupixent [®] (dupilumab) 300mg/2mL and 200mg/1.14mL prefilled pen and syringe; 100mg/0.67mL single-dose prefilled syringe	Interleukin-4 Alpha Antagonists	F, PA, QL, SP	T4, PA, QL, SP	T5, PA, QL, SP
Xarelto [®] (rivaroxaban) 1mg/mL suspension	Anticoagulants	F, PA	T2, QL	T3, QL
insulin aspart protamine and insulin aspart (generic for Novolog [®] 70/30 Mix and Novolog [®]) Vials: 100 units/mL (10mL), FlexPen: 100 units/mL (3mL) <i>Effective Jan. 1, 2022.</i>	Insulin	F, QL	T2, QL	T3, QL
New Generics – Unless otherwise noted, when a generic product becomes available, the brand-name product will be removed from the formularies.				
nebivolol hydrochloride (generic for Bystolic [®]) 2.5mg, 5mg, 10mg, and 20mg tablets	Beta Blockers	NF	T3	T4
paroxetine hydrochloride (generic for Paxil [®]) 10mg/5mL oral suspension	Selective Serotonin Reuptake Inhibitors	F, PA, QL	T3, PA, QL	T4, PA, QL
everolimus (generic for Afinitor Disperz [®]) 2mg, 3mg, and 5mg tablets for oral suspension	Antineoplastic	F, PA, SP	T4, PA, SP	T5, PA, SP
*MB = Medical Benefit, ME = Medical Exception, F = Formulary, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required, AL = Age Limit, BE = Benefit Exclusion				

Centennial, Commercial and Metal Formulary Updates

Drug Name	Therapeutic Class	Centennial Care*	Commercial*	Metal Level Plans*
New Generics (continued)				
nelarabine (generic for Arranon [®]) 5mg/mL intravenous solution	Antimetabolites	ME	ME	MB
naloxone (generic for Narcan [®]) 4mg/0.1mL nasal spray	Opioid Antagonists	F	T2, QL	T3
Other Changes				
Novolog [®] (insulin aspart injection) Vials: 100 units/mL (10mL), Cartridge: 100 units/mL (3mL), Pen-Injector: 100 units/mL (3mL) <i>Removed from Commercial and Metal Level formularies. Effective Jan. 1, 2022.</i>	Insulin	NF	NF	NF
Erbix [®] (cetuximab) Injection: 100mg/50mL or 200mg/100mL in a single-dose vial	Antineoplastic	MB, PA	MB, PA	MB, PA
Truxima [®] (rituximab) 10mg intravenous solution <i>Removed from Centennial Care, Commercial and Metal Level formularies.</i>	Antineoplastic	ME	ME	ME
Austedo [®] (deutetrabenazine) 6mg, 9mg, and 12mg tablets <i>Updated prior authorization criteria.</i>	Central Nervous System Agent	F, PA, QL	T4, PA, QL, SP	T5, PA, QL, SP
Wakix [®] (pitolisant) 8.9mg and 17.8mg tablets <i>Updated prior authorization criteria.</i>	Histamine H3 Antagonist/Inverse Agonist	F, PA, QL, AL	T4, PA, QL, AL	T5, PA, QL, AL
Entresto [®] (sacubitril/valsartan) 24mg/26mg, 49mg/51mg, and 97/103mg tablets <i>Updated prior authorization criteria.</i>	Angiotensin Receptor-Nepriylsin Inhibitors	F, PA, QL	T3, PA, QL, SP	T4, PA, QL, SP
Feraheme [®] (ferumoxytol) 1mg intravenous solution <i>Updated prior authorization criteria.</i>	Iron Replacement Therapies	MB, PA	MB, PA	MB, PA
Ferlecit [®] (ferric gluconate complex in sucrose) 12.5mg intravenous solution <i>Updated prior authorization criteria.</i>	Iron Replacement Therapies	MB, PA	MB, PA	MB, PA
Infed [®] (iron dextran) 50mg intravenous solution <i>Updated prior authorization criteria.</i>	Iron Replacement Therapies	MB, PA	MB, PA	MB, PA
Injectafer [®] (ferric carboxymaltose) 1mg intravenous solution <i>Updated prior authorization criteria.</i>	Iron Replacement Therapies	MB, PA	MB, PA	MB, PA
Venofer [®] (iron sucrose) 1mg intravenous solution <i>Updated prior authorization criteria.</i>	Iron Replacement Therapies	MB, PA	MB, PA	MB, PA
*MB = Medical Benefit, ME = Medical Exception, F = Formulary, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required, AL = Age Limit, BE = Benefit Exclusion				

Medicare Formulary Changes

Drug Name	Coverage*	Date Submitted for Update
Formulary Additions		
Dupixent [®] (dupilumab) 300mg/2mL and 200mg/1.14mL solution in a pre-filled pen and syringe 100mg/0.67mL solution in a single-dose prefilled syringe	T5	03/01/2022
Menquadfi [®] (meningococcal conjugate vaccine) Intramuscular injection	T3	01/01/2022
Prevymis [®] (letemovir) 240mg, 480mg oral tablet	T5	01/01/2022
pilocarpine (Isopto Carpine [®]) 1%, 2%, 4% ophthalmic solution	T2	01/01/2022
testosterone (AndroGel [®]) 1% gel pump	T3	01/01/2022
Formulary Deletions		
Afinitor Disperz [®] (everolimus) 2mg, 3mg, 5mg tablets for oral suspension	NF	02/01/2022
Bystolic [®] (nebivolol hydrochloride) 2.5mg, 5mg, 10mg, 20mg oral tablets	NF	02/01/2022
Carbaglu [®] (carglumic acid) 200mg tablet for oral suspension	NF	03/01/2022
Dexilant [®] (dexlansoprazole) 30mg, 60mg oral capsules	NF	01/01/2022
Narcan [®] (naloxone) 4mg/0.1mL nasal spray	NF	03/01/2022
Paxil [®] (paroxetine hydrochloride) 10mg/5mL oral suspension	NF	02/01/2022
New Generics		
everolimus (generic for Afinitor Disperz [®]) 2mg, 3mg, 5mg tablets for oral suspension	T5	02/01/2022
nebivolol (generic for Bystolic [®]) 2.5mg, 5mg, 10mg, 20mg oral tablet	T4	02/01/2022
carglumic acid (generic for Carbaglu [®]) 200mg tablets for oral suspension	T5	03/01/2022
naloxone (generic for Narcan [®]) 4mg/0.1mL nasal spray	T3	03/01/2022
paroxetine (generic for Paxil [®]) 10mg/5mL oral suspension	T3	02/01/2022
New Products		
Xarelto [®] (rivaroxaban) 1mg/mL oral suspension	T3	03/01/2022
Other Formulary Changes		
testosterone (AndroGel [®]) 25mg/2.5gm gel	T3	01/01/2022
Firvanq [®] (vancomycin) 25mg/mL, 50mg/mL solution	T3	01/01/2022
Rozlytrek [®] (entrectinib) 100mg oral capsule	T5	01/01/2022
Dificid [®] (fidaxomicin) 40mg/mL suspension	T5	01/01/2022
Enbrel [®] 25mg/0.5ml solution	T5	01/01/2022
Linzess [®] 75mcg, 145mcg, 290mcg oral capsules	T4	01/01/2022
clozapine 150mg dispersible oral tablet	T4	01/01/2022
clobazam 2.5mg/mL suspension	T4	01/01/2022
mesalamine (Canasa [®]) 1000mg suppository	T4	01/01/2022
lopinavir/ritonavir (Kaletra [®]) 400-100mg/5mL oral suspension	T4	01/01/2022
Valganciclovir (Valcyte [®]) 450mg oral tablet	T3	01/01/2022
paliperidone (Invega [®]) 9mg extended-release oral tablet	T4	01/01/2022
acitretin 17.5mg oral capsule	T4	01/01/2022
Bydureon Bcise [®] (exenatide extended release) 2mg/0.85mL auto injector	T4	01/01/2022
Prograf [®] (tacrolimus) 0.2mg oral packet	T4	01/01/2022
Bicillin C-R [®] (penicillin G benzathine and procaine) 300,000 unit/mL solution	T4	01/01/2022
*MB = Medical Benefit, ME = Medical Exception, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required, AL = Age Limit, BE = Benefit Exclusion, NDS = Non-Extended Day Supply		

Food and Drug Administration (FDA) Alerts Sept. 21, 2021, to Jan. 6, 2022

For a full list of FDA alerts and additional information, see the FDA website at:

<https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts>.

- 1. Recall of one lot of Glucagon® Emergency Kit (1mg/mL) manufactured by Eli Lilly and Company [Sept. 26, 2021]:** Eli Lilly and Company announced a voluntary, user-level recall of one lot of Glucagon Emergency Kit due to a complaint reporting that the vial of Glucagon was in liquid form instead of the powder form. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency. Patients who are taking this product should consult with their health care provider or pharmacy to determine if they have the affected product lots.
Presbyterian's Response: Informed providers in the Pharmacy & Therapeutics Committee Updates newsletter (P&T newsletter) and sent letters to notify prescribing providers and members with prescription claims for potentially affected lots of medication.
- 2. Recall of specific Lotrimin and Tinactin spray products manufactured by Bayer U.S. LLC [Oct. 1, 2021]:** Bayer announced a voluntary, consumer-level recall of over-the-counter Lotrimin AF and Tinactin spray products due to the presence of benzene in some samples of the products. Benzene is classified as a human carcinogen and is not an ingredient in any Bayer consumer health products, although the levels detected are not expected to cause adverse health consequences. Patients who are taking this product should consult with their healthcare provider if they have questions.
Presbyterian's Response: Informed providers in the P&T newsletter.
- 3. Recall of Lidocaine Hydrochloride (HCl) Topical Solution 4% manufactured by Teligent Pharma [Oct. 12, 2021]:** Teligent Pharma, Inc. announced a voluntary, consumer-level recall of five lots of Lidocaine HCl Topical Solution 4% packaged in 50mL screw cap glass bottles because the firm's testing has found it to be super potent based on an out-of-specification (OOS) result obtained at the 18-month stability time point. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Presbyterian's Response: Informed providers in the P&T newsletter and sent letters to notify prescribing providers and members with prescription claims for potentially affected lots of medication.
- 4. Recall of Irbesartan, Irbesartan and Hydrochlorothiazide tablets manufactured by Lupin Pharmaceuticals Inc. [Oct. 14, 2021]:** Lupin Pharmaceuticals, Inc. announced a voluntary, consumer-level recall of certain lots of Irbesartan, Irbesartan and Hydrochlorothiazide (HCTZ) tablets due to the presence of N-nitrosoirbesartan. Lupin discontinued the marketing of Irbesartan, Irbesartan and HCTZ tabs on Jan. 7, 2021, and notified its wholesalers, distributors, drug chains, mail order pharmacies and supermarkets by phone and through recall notifications. Lupin is currently arranging for the return of all recalled product lots.
Presbyterian's Response: Informed providers in the P&T newsletter.
- 5. Recall of Cubicin® (Daptomycin for injection) 500mg manufactured by Merck [Oct. 20, 2021]:** Merck announced a voluntary, user-level recall of one lot of Cubicin® (Daptomycin for injection) due to the presence of particulate matter identified as glass particles. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Presbyterian's Response: Informed providers in the P&T newsletter and letters were sent out to notify prescribing providers and members who had prescription claims for potentially affected lots of medication.
- 6. Recall of Levetiracetam injection manufactured by Sagent Pharmaceuticals, Inc. [Nov. 22, 2021]:** Sagent Pharmaceuticals, Inc. announced a voluntary, user-level recall of four lots of Levetiracetam injection due to a lack of sterility assurance. The lack of container closure integrity found in reserve sample vials may result in a non-sterile product. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.
Presbyterian's Response: Informed providers in the P&T newsletter.

7. **Recall of Lidocaine HCl Topical Solution 4% manufactured by Teligent Pharma [Dec. 7, 2021]:** Teligent Pharma, Inc. announced a voluntary, consumer-level recall of two lots of Lidocaine HCl Topical Solution 4% packaged in 50mL screw cap glass bottles because the firm's testing has found it to be super potent based on an OOS result obtained at the 18-month stability time point. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Presbyterian's Response: Informed providers in the P&T newsletter and sent letters to notify prescribing providers and members with prescription claims for potentially affected lots of medication.

8. **Recall of Clobetasol Propionate Ointment USP, 0.05%, packaged in 60g tubes manufactured by Taro Pharmaceuticals USA, Inc. [Dec. 30, 2021]:** Taro Pharmaceuticals USA, Inc. announced a voluntary, consumer-level recall of Clobetasol Propionate Ointment USP, 0.05% packaged in 60g tubes due to the presence of *Ralstonia pickettii* bacteria. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Presbyterian's Response: Informed providers in the P&T newsletter and sent letters to notify prescribing providers and members with prescription claims for potentially affected lots of medication.

NOTE: Notification is sent to Presbyterian members regarding Class I or II drug recalls or market withdrawals due to a drug safety issue. Notifications regarding drug recalls that are lot-specific are not required as it is not possible for Presbyterian to identify members who were dispensed a specific lot of a medication.

Presbyterian formularies and updates, including preferences and restrictions (e.g., quantity limits, step therapy and prior authorization criteria) are available online at the following link:

www.phs.org/providers/formularies.

Current and past issues of the Pharmacy & Therapeutics (P&T) Committee Provider Updates are available online at www.phs.org/providers/formularies.

The Universal Practitioner and Provider Manual and the Centennial Care Practitioner and Provider Manual are also available online at www.phs.org/providermanual and include information about pharmacy benefits, the prior authorization process, generic substitution and requesting non-formulary medications based on medical necessity. Providers may receive a printed copy of both provider manuals at no cost from Presbyterian by contacting their Provider Network Operations relationship executive. Providers may find their relationship executive's contact information at www.phs.org/ContactGuide.

Formulary Search App

As a reminder, Presbyterian formularies are also accessible through the Managed Markets Insights & Technology, LLC (MMIT) Formulary Search App. No registration, username or passwords are required.


Search from your desktop at www.FormularyLookup.com or download the free app today.

Formulary Search

#1 drug formulary app on the web



"Take the guesswork out of selecting medications for your patients and reduce staff time spent on getting authorizations"



Requests for Formulary Additions, Deletions or Modifications

Use the [Formulary Addition Request form](#) to request medication additions, deletions or other changes to the Presbyterian formularies. Please complete and submit the form to the ASK PHP P&T mailbox at askphppt@phs.org. The form can be accessed at http://docs.phs.org/idc/groups/public/documents/communication/pel_00251399.pdf.

Presbyterian Health Plan Formularies

Presbyterian strives to give our providers access to the information and support they need. One way we do this is by providing information on medications that are covered by the plan. Presbyterian formularies may be accessed in the following ways:

- Searchable formularies are available on the Formularies page of the provider website at the following link: www.phs.org/providers/formularies. Providers may search for a drug using this tool by viewing an alphabetical list of drugs, searching by drug name or searching by therapeutic class. Providers may also learn if a covered drug has any restrictions by clicking on the link for the drug.
- Providers can access PDF versions of Presbyterian formularies and updates, including preferences and restrictions (e.g., quantity limits, step therapy and prior authorization criteria), on the Formularies page of the provider website at the link previously provided.
- Presbyterian formularies may also be accessed using the MMIT Formulary Search App. Registration, username or passwords are not required. Search from your desktop at www.FormularyLookup.com, or download the free app from the App Store or Google Play.

Contact Us

Changes to our formularies are based on requests from our practitioners and the recommendations of the P&T Committee. We value your input. If you have any questions or concerns, please email the ASK PHP P&T mailbox at askphppt@phs.org.

For any questions about the formulary coverage of medications, please call Presbyterian's Pharmacy Services Help Desk at (505) 923-5500 or toll-free at 1-888-923-5757. Help Desk business hours are Monday through Friday, from 8 a.m. to 5 p.m. You may also email ASKRX at ASKRX@phs.org. The email box is monitored during regular business hours, Monday through Friday, from 8 a.m. to 5 p.m., and one of our clinical pharmacists will respond within one business day.